血液科指南

订阅

MedSci主页 / 所有栏目 / 血液科指南

原发性中枢神经系统淋巴瘤的MRI和PET成像共识建议：国际原发性中枢神经系统淋巴瘤协作组（IPCG）的指南声明

2021-02-09 国际原发性中枢神经系统淋巴瘤协作组（IPCG） Neuro-Oncology, noab020

淋巴瘤

原发性中枢神经系统淋巴瘤（PCNSL）的先进分子和病理生理学表征揭示了对有前途的靶向治疗方法的见识。医学成像在PCNSL诊断，分期和反应评估中起着基本作用。机构影像学变化和临床试验报告不一致会降低临床

中文标题：

原发性中枢神经系统淋巴瘤的MRI和PET成像共识建议：国际原发性中枢神经系统淋巴瘤协作组（IPCG）的指南声明

英文标题：

Consensus Recommendations for MRI and PET Imaging of Primary Central Nervous System Lymphoma: Guideline Statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)

发布机构：

国际原发性中枢神经系统淋巴瘤协作组（IPCG）

发布日期：

2021-02-09

简要介绍：

原发性中枢神经系统淋巴瘤（PCNSL）的先进分子和病理生理学表征揭示了对有前途的靶向治疗方法的见识。医学成像在PCNSL诊断，分期和反应评估中起着基本作用。机构影像学变化和临床试验报告不一致会降低临床反应评估的可靠性和可重复性。在此背景下，我们旨在：1）严格审查PCNSL背景下先进PET和MRI的使用； 2）提供来自国际临床站点调查的结果，描述了常规和高级成像的当前做法，并且3）提供了国际PCNSL合作小组（IPCG）基于生物学的建议，以适应标准化的成像做法。 IPCG根据先前对原发性和转移性疾病的标准化脑肿瘤成像协议（BTIP）的建议，提供了PET和MRI共识建议。提供了一种生物集成的方法来解决与PCNSL成像评估相关的独特挑战。详细的成像参数有助于研究人员和临床医生采用这些建议。为了提高临床可行性，我们在3T和1.5T MR系统上开发了“理想”和“最低标准”协议，这将促进广泛采用。

相关资料下载：
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=740781c0020536e5, title=原发性中枢神经系统淋巴瘤的MRI和PET成像共识建议：国际原发性中枢神经系统淋巴瘤协作组（IPCG）的指南声明 , enTitle=Consensus Recommendations for MRI and PET Imaging of Primary Central Nervous System Lymphoma: Guideline Statement from the International Primary CNS Lymphoma Collaborative Group (IPCG) , guiderFrom=Neuro-Oncology, noab020, authorId=0, author=, summary=原发性中枢神经系统淋巴瘤（PCNSL）的先进分子和病理生理学表征揭示了对有前途的靶向治疗方法的见识。医学成像在PCNSL诊断，分期和反应评估中起着基本作用。机构影像学变化和临床试验报告不一致会降低临床, cover=, journalId=0, articlesId=null, associationId=1932, associationName=国际原发性中枢神经系统淋巴瘤协作组（IPCG）, associationIntro=国际原发性中枢神经系统淋巴瘤协作组（IPCG）, copyright=0, guiderPublishedTime=Tue Feb 09 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span class="VIiyi" lang="zh-CN"><span class="JLqJ4b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0">原发性中枢神经系统淋巴瘤（PCNSL）的先进分子和病理生理学表征揭示了对有前途的靶向治疗方法的见识。医学成像在PCNSL诊断，分期和反应评估中起着基本作用。机构影像学变化和临床试验报告不一致会降低临床反应评估的可靠性和可重复性。在此背景下，我们旨在：1）严格审查PCNSL背景下先进PET和MRI的使用； 2）提供来自国际临床站点调查的结果，描述了常规和高级成像的当前做法，并且3）提供了国际PCNSL合作小组（IPCG）基于生物学的建议，以适应标准化的成像做法。 IPCG根据先前对原发性和转移性疾病的标准化脑肿瘤成像协议（BTIP）的建议，提供了PET和MRI共识建议。提供了一种生物集成的方法来解决与PCNSL成像评估相关的独特挑战。详细的成像参数有助于研究人员和临床医生采用这些建议。为了提高临床可行性，我们在3T和1.5T MR系统上开发了&ldquo;理想&rdquo;和&ldquo;最低标准&rdquo;协议，这将促进广泛采用。</span></span></p>, tagList=[TagDto(tagId=412, tagName=淋巴瘤)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=40, categoryName=影像放射, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4543, appHits=110, showAppHits=0, pcHits=860, showPcHits=4431, likes=1, shares=5, comments=7, approvalStatus=1, publishedTime=Wed Feb 10 19:28:25 CST 2021, publishedTimeString=2021-02-09, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Wed Feb 10 19:28:18 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 14:01:38 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1008722, encodeId=b05d1008e22ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:37:16 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976495, encodeId=78d49e64955f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60b22056515, createdName=1381ecf10dm, createdTime=Thu Jun 24 11:51:17 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968373, encodeId=4b3f9683e344, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58a05507417, createdName=sonyhlm, createdTime=Tue May 25 14:43:32 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967368, encodeId=3a1096e36829, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f94874946, createdName=tyiutyu16, createdTime=Fri May 21 01:33:02 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924232, encodeId=60c69242326f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 12 07:46:14 CST 2021, time=2021-02-12, status=1, ipAttribution=)]
    2021-08-17 ms1000001256854968

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1008722, encodeId=b05d1008e22ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:37:16 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976495, encodeId=78d49e64955f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60b22056515, createdName=1381ecf10dm, createdTime=Thu Jun 24 11:51:17 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968373, encodeId=4b3f9683e344, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58a05507417, createdName=sonyhlm, createdTime=Tue May 25 14:43:32 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967368, encodeId=3a1096e36829, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f94874946, createdName=tyiutyu16, createdTime=Fri May 21 01:33:02 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924232, encodeId=60c69242326f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 12 07:46:14 CST 2021, time=2021-02-12, status=1, ipAttribution=)]
    2021-06-24 1381ecf10dm

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1008722, encodeId=b05d1008e22ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:37:16 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976495, encodeId=78d49e64955f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60b22056515, createdName=1381ecf10dm, createdTime=Thu Jun 24 11:51:17 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968373, encodeId=4b3f9683e344, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58a05507417, createdName=sonyhlm, createdTime=Tue May 25 14:43:32 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967368, encodeId=3a1096e36829, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f94874946, createdName=tyiutyu16, createdTime=Fri May 21 01:33:02 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924232, encodeId=60c69242326f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 12 07:46:14 CST 2021, time=2021-02-12, status=1, ipAttribution=)]
    2021-05-25 sonyhlm

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1008722, encodeId=b05d1008e22ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:37:16 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976495, encodeId=78d49e64955f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60b22056515, createdName=1381ecf10dm, createdTime=Thu Jun 24 11:51:17 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968373, encodeId=4b3f9683e344, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58a05507417, createdName=sonyhlm, createdTime=Tue May 25 14:43:32 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967368, encodeId=3a1096e36829, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f94874946, createdName=tyiutyu16, createdTime=Fri May 21 01:33:02 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924232, encodeId=60c69242326f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 12 07:46:14 CST 2021, time=2021-02-12, status=1, ipAttribution=)]
    2021-05-21 tyiutyu16

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1008722, encodeId=b05d1008e22ac, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:37:16 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976495, encodeId=78d49e64955f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60b22056515, createdName=1381ecf10dm, createdTime=Thu Jun 24 11:51:17 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=968373, encodeId=4b3f9683e344, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58a05507417, createdName=sonyhlm, createdTime=Tue May 25 14:43:32 CST 2021, time=2021-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967368, encodeId=3a1096e36829, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f94874946, createdName=tyiutyu16, createdTime=Fri May 21 01:33:02 CST 2021, time=2021-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924232, encodeId=60c69242326f, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 12 07:46:14 CST 2021, time=2021-02-12, status=1, ipAttribution=)]
    2021-02-12 carrotlyl

    感谢分享

    0

相关指南

2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：巨球蛋白血症/淋巴浆细胞性淋巴瘤

日本血液学会(JSH,Japanese Society of Hematology) · 2019-09-07

2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：边缘区淋巴瘤

日本血液学会(JSH,Japanese Society of Hematology) · 2019-08-19

2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：伯基特淋巴瘤

日本血液学会(JSH,Japanese Society of Hematology) · 2019-07-11

2018 JSH实践指南：血液恶性肿瘤—淋巴瘤：滤泡性淋巴瘤

日本血液学会(JSH,Japanese Society of Hematology) · 2019-06-06

2018 JSH实践指南：血液恶性肿瘤—成人T细胞白血病-淋巴瘤-9.结节外NK／T细胞淋巴瘤（鼻型）

日本血液学会(JSH,Japanese Society of Hematology) · 2019-02-28

造血干细胞移植治疗淋巴瘤中国专家共识（2018版）

中国抗癌协会血液肿瘤专业委员会 · 2019-01-16